News
IMNM
15.46
-1.84%
-0.29
Weekly Report: what happened at IMNM last week (0429-0503)?
Weekly Report · 22h ago
IMMUNOME APPOINTS KINNEY HORN AS CHIEF BUSINESS OFFICER
Reuters · 4d ago
Immunome Announces Executive Shift, Welcomes New Accounting Officer
TipRanks · 6d ago
Immunome Initiated at Overweight by JP Morgan
Dow Jones · 6d ago
Immunome Price Target Announced at $24.00/Share by JP Morgan
Dow Jones · 6d ago
JP Morgan Initiates Coverage On Immunome with Overweight Rating, Announces Price Target of $24
Benzinga · 6d ago
Analysts Offer Insights on Healthcare Companies: Immunome (IMNM), Dyne Therapeutics (DYN) and Dexcom (DXCM)
TipRanks · 04/30 09:01
U.S. RESEARCH ROUNDUP-Domino's Pizza, HCA Healthcare, WW Grainger
Wall Street analysts revise their ratings and price targets on several U.S.-listed companies. Domino's Pizza, HCA Healthcare, WW Grainger and Molina Healthcare among companies. Abbvie Inc. And others have seen their targets cut by some analysts.
Reuters · 04/30 07:05
IMMUNOME INC <IMNM.O>: JP MORGAN INITIATES COVERAGE WITH OVERWEIGHT RATING; PRICE TARGET $24
Reuters · 04/30 04:22
Weekly Report: what happened at IMNM last week (0422-0426)?
Weekly Report · 04/29 12:03
Immunome Inc: Other definitive proxy statementsOpen document
Press release · 04/27 07:22
Immunome Appoints Sandra Swain and Revises Audit Committee
TipRanks · 04/25 20:12
*Immunome Appoints Sandra Swain to Board of Directors
Dow Jones · 04/25 12:26
Weekly Report: what happened at IMNM last week (0415-0419)?
Weekly Report · 04/22 11:50
Weekly Report: what happened at IMNM last week (0408-0412)?
Weekly Report · 04/15 11:40
Immunome Initiated at Buy by Guggenheim
Dow Jones · 04/15 10:43
Immunome Price Target Announced at $35.00/Share by Guggenheim
Dow Jones · 04/15 10:43
Guggenheim Initiates Coverage On Immunome with Buy Rating, Announces Price Target of $35
Benzinga · 04/15 10:34
Zentalis Pharmaceuticals: Data In 1st Half Of 2024 Could Get The Ball Rolling
Zentalis Pharmaceuticals, Inc. Expects final results from phase 1b study of azenosertib for the treatment of patients with osteosarcoma in the 1st half of 2024. Zentalis is working on advancing its lead candidate in its pipeline. The drug could be approved for a gynecological indication in 2026.
Seeking Alpha · 04/12 18:12
Weekly Report: what happened at IMNM last week (0401-0405)?
Weekly Report · 04/08 11:46
More
Webull provides a variety of real-time IMNM stock news. You can receive the latest news about Immunome Inc through multiple platforms. This information may help you make smarter investment decisions.
About IMNM
Immunome, Inc. is a biotechnology company engaged in developing targeted cancer therapies. The Company's portfolio pursues each target with a modality appropriate to its biology, including immunotherapies, radioligand therapies and Antibody-Drug Conjugates (ADCs). Its memory B cell hybridoma technology allows for the screening and functional characterization of novel antibodies and targets. Its programs include Oncology (IMM-ONC-01), LU FAP, and SARS-CoV-2 (IMM-BCP-01). The oncology program is an antibody (IMM-ONC-01) against interleukin-38 (IL-38) a novel immune modulator for the treatment of various solid tumors. Its Targeted Effector platform uses small molecule ligands to selectively deliver drug payloads to diseased cells. It also operates AL102 and related drug candidate AL101. AL102 is an investigational small molecule gamma secretase inhibitor being evaluated in the Phase III for the treatment of desmoid tumors. AL102 is a potential once-daily oral treatment for desmoid tumors.